0001209191-22-005118.txt : 20220126
0001209191-22-005118.hdr.sgml : 20220126
20220126195328
ACCESSION NUMBER: 0001209191-22-005118
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220125
FILED AS OF DATE: 20220126
DATE AS OF CHANGE: 20220126
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Detheux Michel
CENTRAL INDEX KEY: 0001816196
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 22559360
MAIL ADDRESS:
STREET 1: C/O ITEOS THERAPEUTICS, INC.
STREET 2: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: iTeos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001808865
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 857-204-4583
MAIL ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-25
0
0001808865
iTeos Therapeutics, Inc.
ITOS
0001816196
Detheux Michel
139 MAIN STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Executive Officer
Common Stock
2022-01-25
4
S
0
10088
35.45
D
53612
D
Common Stock
2022-01-25
4
S
0
4412
36.21
D
49200
D
The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.96 to $35.91, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.99 to $36.75, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Adi Osovsky, as Attorney-in-Fact
2022-01-26